ArticleTherapeutic advances in chronic disease2011
Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials.
Article in Therapeutic advances in chronic disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- A randomized control trial to assess the impact of vitamin D supplementation compared to placebo on vascular stiffness in chronic kidney disease patients.BMC cardiovascular disorders · 2014Trial
- Predicting 1-year successful clinical use of an arteriovenous access for hemodialysis using machine learning.NPJ digital medicine · 2025Article
- Key Performance Indicators of Secondary Health Care in Chronic Kidney Disease: Experience in Public and Private Services in the State of São Paulo, Brazil.International journal of nephrology · 2024Article
- The potential effect of natural antioxidants on endothelial dysfunction associated with arterial hypertension.Frontiers in cardiovascular medicine · 2024Review
- The role of gut-dependent molecule trimethylamine N-oxide as a novel target for the treatment of chronic kidney disease.International urology and nephrology · 2023Review
- Article
- Value of troponin T as a screening test of cardiac structure and function in chronic kidney disease.Global cardiology science & practice · 2021Article
- Data Challenges in Addressing Chronic Kidney Disease in Low- and Lower-Middle-Income Countries.Kidney international reports · 2021Review
- Review
- Article
- Mechanisms of Cardiovascular Disorders in Patients With Chronic Kidney Disease: A Process Related to Accelerated Senescence.Frontiers in cell and developmental biology · 2020Review
- Nutraceuticals as a potential adjunct therapy toward improving vascular health in CKD.American journal of physiology. Regulatory, integrative and comparative physiology · 2019Review
- Review
- Exosomes: a potential key target in cardio-renal syndrome.Frontiers in immunology · 2014Review
- Erythropoietin in the critically ill: do we ask the right questions?Critical care (London, England) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease is the leading cause of death and morbidity in people with chronic kidney disease (CKD) making measures to modify cardiovascular risk a clinical priority. The relationship between risk factors and cardiovascular outcomes is often substantially different in people with CKD compared with the general population, leading to uncertainty around pathophysiological mechanisms and the validity of generalizations from the general population. Furthermore, published reports of subgroup analyses from clinical trials have suggested that a range of interventions may have different effects in people with kidney disease compared with those with normal kidney function. There is a relative scarcity of randomized controlled trials (RCTs) conducted in CKD populations, and most such trials are small and underpowered. As a result, evidence to support cardiovascular risk modification measures for people with CKD is largely derived from small trials and post hoc analyses of RCTs conducted in the general population. In this review, we examine the available RCT evidence on interventions aimed at preventing cardiovascular events in people with kidney disease to identify beneficial treatments as well as current gaps in knowledge that should be a priority for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.